Rini Brian I
Department of Solid Tumor Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH 44195, USA.
Clin Genitourin Cancer. 2005 Dec;4(3):175-80. doi: 10.3816/CGC.2005.n.029.
Several molecular pathways are implicated in renal cell carcinoma (RCC) pathogenesis, including the von Hippel-Lindau gene inactivation leading to vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) expression. SU11248 and AG013736 are small-molecule inhibitors of the tyrosine kinase portion of the VEGF and PDGF receptors. Substantial clinical activity has been reported for these agents in metastatic RCC trials, leading to additional investigations in a variety of settings.
几种分子途径与肾细胞癌（RCC）的发病机制有关，包括导致血管内皮生长因子（VEGF）和血小板衍生生长因子（PDGF）表达的冯·希佩尔-林道基因失活。SU11248和AG013736是VEGF和PDGF受体酪氨酸激酶部分的小分子抑制剂。在转移性RCC试验中已报道这些药物具有显著的临床活性，从而引发了在多种情况下的进一步研究。
